Abstract 157P
Background
The major breakthrough in cancer therapy with immune checkpoint inhibitors (ICIs) has highlighted the important role of these molecules in antitumoral immunity. However, most patients do not achieve durable responses, making biomarker research in this setting essential. We aimed at testing circulating concentrations of soluble CD27 (sCD27) and CD27 bound to extracellular vesicles (EVs) as potential biomarkers to predict response and overall survival (OS) in patients undergoing ICI.
Methods
Serum and plasma levels of sCD27 were assessed by multiplex immunoassay in three patient cohorts (n=187) with advanced solid malignancies including longitudinal samples (n=126): a training (n=84, 210 specimens, Aachen ICI) and validation cohort (n=70, 70 specimens, Hamburg ICI)), both treated with ICI therapy, and a second independent validation cohort (n=33, 33 specimens, Hamburg non-ICI) undergoing systemic therapy without any ICI. In a subset (n=36, 36 baseline and 108 longitudinal specimens), EV-bound CD27 from serum was measured, while EV characterization studies were conducted on a fourth cohort (n=45).
Results
In the Aachen and Hamburg ICI cohorts, patients with lower circulating sCD27 levels before and during ICI therapy had a significantly longer progression-free survival (PFS) and OS compared to patients with higher levels, a finding that was confirmed by multivariate analysis (Aachen ICI: pPFS=0.012, pOS=0.001; Hamburg ICI: pPFS=0.040, pOS=0.004). This finding could not be replicated in the Hamburg non-ICI cohort, providing a rationale for the predictive biomarker role of sCD27 in immune checkpoint blockade. Remarkably, EV-bound CD27 baseline and dynamics during ICI therapy also emerged as a potent predictive biomarker, acting however antagonistically to soluble sCD27, whereas in this case patients with higher levels showed a clear PFS and OS benefit. A combined “multi-CD27” score including both molecules showed the best predictive ability (HRPFS: 17.21 with p<0.001, HROS: 6.47 with p=0.011).
Conclusions
Soluble and EV-bound CD27 appear to have opposing immunomodulatory functions and may represent easily measurable, non-invasive prognostic markers to predict response and survival in patients under ICI therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ERC, BMBF, DFG, DKH, Ernst-Jung Foundation, UCCH.
Disclosure
J. Von Felden: Financial Interests, Institutional, Other, Honoraries: Roche, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08